Want to see SENS full AI Analyst Report?
Top Page
Senseonics Holdings
(NASDAQ:SENS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$8.50
▼(-8.99% Downside)
Action:Reiterated
Date:09/07/26
The score is held back primarily by weak financial sustainability—large ongoing losses and accelerating cash burn outweigh improving revenue and gross margin. Technicals are a key offset, with strong upward price momentum above major moving averages, though indicators are nearing overbought. Valuation remains challenged due to negative earnings, while the recent European asset deals add a modest strategic positive.
Positive Factors
Improving Revenue and Gross Margin
Rising revenue alongside materially stronger gross margin indicates improving product economics and growing commercial traction. If sustained, this combination can expand contribution toward operating costs, support reinvestment in Eversense, and improve the long-term path to profitability.
Negative Factors
Large and Widening Losses
Very large and widening losses show that operating expenses still substantially exceed the current revenue base. Unless growth and gross-margin gains outpace spending, persistent losses could delay profitability, require additional financing, and limit the company’s ability to invest from internal earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue and Gross Margin
Rising revenue alongside materially stronger gross margin indicates improving product economics and growing commercial traction. If sustained, this combination can expand contribution toward operating costs, support reinvestment in Eversense, and improve the long-term path to profitability.
Read all positive factors
Senseonics Holdings (SENS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$421.41M
Dividend YieldN/A
Average Volume (3M)678.43K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth90.63%
EPS Growth-11.42%
CountryUS
Employees130
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.27
Shares Outstanding52,874,054
10 Day Avg. Volume567,098
30 Day Avg. Volume678,433
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue5.12
Enterprise Value/Gross Profit9.33
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$12.00Price Target Upside28.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.28
Revenue Forecast (FY)$64.24M
Senseonics Holdings Business Overview & Revenue Model
Company Description
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the U...
How the Company Makes Money
Senseonics makes money primarily by commercializing its Eversense CGM platform and associated consumables and services. Revenue is generated from sales of CGM products (notably implantable sensors and related system components) and from supplying ...
Senseonics Holdings Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.Positive Updates
Strong Q1 Revenue and Year-over-Year Growth
Net revenue of $11.7 million in Q1 2026, an 85% increase versus $6.3 million in Q1 2025; U.S. revenue $9.3 million and international $2.4 million.
Negative Updates
Higher Operating Expenses and Increased Net Loss
Q1 2026 net loss of $32.3M ($0.71 per share) versus $14.3M ($0.40) in Q1 2025 — an increase of $18.0M; SG&A of $30.2M (up $22.5M year-over-year) driven by commercial integration, transition services and DTC marketing; R&D of $8.6M (up $1.3M).
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue and Year-over-Year Growth
Net revenue of $11.7 million in Q1 2026, an 85% increase versus $6.3 million in Q1 2025; U.S. revenue $9.3 million and international $2.4 million.
Read all positive updates
Company Guidance
Senseonics raised full‑year 2026 global net revenue guidance to $60–$64 million (from $58–$62M), implying year‑over‑year growth of ~70%–82%; Q1 revenue was $11.7M (up 85% YoY from $6.3M) with gross profit $6.9M and a 58% gross margin (adjusted ~54%), and the company now expects full‑year gross profit margin of 55%–58% with seasonality ~40% H1 / 60% H2. Management guided 2026 operating expenses of $150–$160M and cash utilization of $110–$120M; cash at March 31 was $64.6M, debt and accrued interest $35.2M (total debt outstanding $55M after a $20M draw), the Hercules facility was expanded from $100M to $140M with up to $85M additional availability, and the company raised $92M in gross equity proceeds. Key commercial metrics: planned DTC spend ~ $13M in 2026, DTC drove ~60% of Q1 new patient shipments (HCP ~40%), bundled‑pay now ~60% of volume, reorders expected to be ~40% of U.S. volume, Eon Care performs >1/3 of insertions, and Senseonics expects to double U.S. patients this year.Senseonics Holdings Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.55M | 35.26M | 22.47M | 22.39M | 16.39M | 13.68M |
| Gross Profit | 26.64M | 15.76M | 533.00K | 3.09M | 2.73M | -811.00K |
| EBITDA | -102.37M | -62.65M | -68.70M | -48.01M | 161.81M | -284.51M |
| Net Income | -109.39M | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M |
Balance Sheet | ||||||
| Total Assets | 176.84M | 126.27M | 100.44M | 138.22M | 177.67M | 198.93M |
| Cash, Cash Equivalents and Short-Term Investments | 142.66M | 94.03M | 74.60M | 109.46M | 144.01M | 129.91M |
| Total Debt | 61.84M | 41.37M | 61.05M | 47.78M | 75.38M | 64.21M |
| Total Liabilities | 86.52M | 65.22M | 116.99M | 64.77M | 180.25M | 384.46M |
| Stockholders Equity | 90.31M | 61.05M | -16.55M | 73.45M | -2.58M | -185.53M |
Cash Flow | ||||||
| Free Cash Flow | -96.83M | -60.24M | -62.70M | -70.51M | -66.62M | -56.29M |
| Operating Cash Flow | -95.94M | -59.13M | -60.47M | -70.16M | -66.31M | -56.08M |
| Investing Cash Flow | -3.85M | -53.42M | 32.84M | 89.71M | 26.88M | -148.75M |
| Financing Cash Flow | 113.03M | 78.19M | 26.83M | 20.37M | 41.76M | 220.08M |
Senseonics Holdings Technical Analysis
Negative
9.34
Price Trends
9.16
Negative
7.54
Positive
7.15
Positive
Market Momentum
-0.33
Positive
37.61
Neutral
18.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 9.34 is above the 20-day moving average (MA) of 9.21, above the 50-day MA of 9.16, and above the 200-day MA of 7.15, indicating a neutral trend. The MACD of -0.33 indicates Positive momentum. The RSI at 37.61 is Neutral, neither overbought nor oversold. The STOCH value of 18.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.
Senseonics Holdings Risk Analysis
Senseonics Holdings disclosed 69 risk factors in its most recent earnings report. Senseonics Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our recent exchange agreements with certain holders of our 2025 Notes will result in additional dilution and could cause our stock price to decline. Q3, 2023
Senseonics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $30.29B | 30.99 | 36.19% | ― | 15.54% | 77.43% | |
69 Neutral | $4.39B | 22.74 | 15.41% | ― | 12.39% | ― | |
68 Neutral | $9.89B | 26.47 | 26.69% | ― | 29.41% | 59.39% | |
54 Neutral | $421.41M | -3.51 | -165.83% | ― | 90.63% | -11.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.15B | -17.61 | -45.97% | ― | 3.92% | 70.03% | |
44 Neutral | $42.51M | -3.60 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
SENS
Senseonics Holdings
7.40
0.05
0.68%
DXCM
Dexcom
78.32
7.26
10.22%
PODD
Insulet
148.12
-175.34
-54.21%
TNDM
Tandem Diabetes Care
17.15
2.49
16.98%
LIVN
LivaNova
81.27
26.82
49.26%
XTNT
Xtant Medical Holdings
0.31
-0.46
-59.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.